Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling

(2017) Markus Brockmann et al.   NATURE

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

What does PD-L1 positive or negative mean?

(2016) Antoni Ribas et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

(2016) Keisuke Kataoka et al.   NATURE

Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9

(2016) John G Doench et al.   NATURE BIOTECHNOLOGY

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

(2016) Paul T. Nghiem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity

(2016) R. D. Dorand et al.   SCIENCE

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts

(2015) K. Kemper et al.   EMBO Molecular Medicine

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

A generic strategy for CRISPR-Cas9-mediated gene tagging

(2015) Daniel H. Lackner et al.   Nature Communications

Identification of the Common Origins of Osteoclasts, Macrophages, and Dendritic Cells in Human Hematopoiesis

(2015) Yanling Xiao et al.   Stem Cell Reports

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

The Ubiquitin Ligase Stub1 Negatively Modulates Regulatory T Cell Suppressive Activity by Promoting Degradation of the Transcription Factor Foxp3

(2013) Zuojia Chen et al.   IMMUNITY

Strength of PD-1 signaling differentially affects T-cell effector functions

(2013) F. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of CMTM7 as a Transmembrane Linker of BLNK and the B-Cell Receptor

(2012) Atsuko Miyazaki et al.   PLoS One

Ebola virus entry requires the cholesterol transporter Niemann–Pick C1

(2011) Jan E. Carette et al.   NATURE

Haploid Genetic Screens in Human Cells Identify Host Factors Used by Pathogens

(2009) J. E. Carette et al.   SCIENCE